| Literature DB >> 32271161 |
Paul Dembny1, Andrew G Newman1, Manvendra Singh2, Michael Hinz2, Michal Szczepek3, Christina Krüger1, Robert Adalbert4, Omar Dzaye2,5,6, Thorsten Trimbuch7, Thomas Wallach1, Gunnar Kleinau3, Katja Derkow1, Bernhard C Richard8, Carola Schipke9,10,11, Claus Scheidereit2, Harald Stachelscheid12, Douglas Golenbock13, Oliver Peters9,10,11, Michael Coleman14, Frank L Heppner7,8,11, Patrick Scheerer3,15, Victor Tarabykin1, Klemens Ruprecht16, Zsuzsanna Izsvák2, Jens Mayer17, Seija Lehnardt1,16.
Abstract
Although human endogenous retroviruses (HERVs) represent a substantial proportion of the human genome and some HERVs, such as HERV-K(HML-2), are reported to be involved in neurological disorders, little is known about their biological function. We report that RNA from an HERV-K(HML-2) envelope gene region binds to and activates human Toll-like receptor (TLR) 8, as well as murine Tlr7, expressed in neurons and microglia, thereby causing neurodegeneration. HERV-K(HML-2) RNA introduced into the cerebrospinal fluid (CSF) of either C57BL/6 wild-type mice or APPPS1 mice, a mouse model for Alzheimer's disease (AD), resulted in neurodegeneration and microglia accumulation. Tlr7-deficient mice were protected against neurodegenerative effects but were resensitized toward HERV-K(HML-2) RNA when neurons ectopically expressed murine Tlr7 or human TLR8. Transcriptome data sets of human AD brain samples revealed a distinct correlation of upregulated HERV-K(HML-2) and TLR8 RNA expression. HERV-K(HML-2) RNA was detectable more frequently in CSF from individuals with AD compared with controls. Our data establish HERV-K(HML-2) RNA as an endogenous ligand for species-specific TLRs 7/8 and imply a functional contribution of human endogenous retroviral transcripts to neurodegenerative processes, such as AD.Entities:
Keywords: Alzheimer’s disease; Immunology; Innate immunity; Neurodegeneration; Neuroscience
Mesh:
Substances:
Year: 2020 PMID: 32271161 PMCID: PMC7205273 DOI: 10.1172/jci.insight.131093
Source DB: PubMed Journal: JCI Insight ISSN: 2379-3708